GSCF Statement on new Lancet systematic review and meta-analysis on paracetamol safety during pregnancy
Following renewed public discussion regarding paracetamol use during pregnancy and potential neurodevelopmental outcomes, GSCF notes important new evidence from a systematic review and meta-analysis published in The Lancet Obstetrics, Gynaecology & Women’s Health. This comprehensive analysis found no evidence that paracetamol use during pregnancy increases the risk of autism spectrum disorder, attention-deficit hyperactivity disorder (ADHD), or intellectual disability in children, particularly when higher-quality study designs such as sibling-comparison analyses were prioritized.
These findings support existing recommendations that paracetamol can be used during pregnancy when taken as directed, and reinforce the importance of ensuring pregnant individuals have access to safe and effective options for managing pain and fever. Avoiding appropriate treatment may expose pregnant individuals and their babies to known risks associated with untreated fever and severe pain.
GSCF strongly supports continued high-quality, independent research to further strengthen the evidence base and improve study methods, including more consistent exposure measurement and long-term follow-up. We also emphasize the importance of empowering individuals with clear, evidence-based information to guide safe and effective self-care practices, and we encourage pregnant individuals to speak with their doctor, pharmacist, or midwife if they have any questions about medicines use during pregnancy.